JAMA Oncology

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

JAMA Oncology
Sep 6, 2024, 13:41 | Blog
Erman Akkus: Mismatch repair in pancreatic cancer
Erman Akkus posted on X about recent paper by Catherine A. O’Connor et al., titled…
Sep 3, 2024, 16:29 | Insight
Jarushka Naidoo: Clinical + genetic factors associated with Type I diabetes from ICIs
Jarushka Naidoo shared a post on X: "Clinical + genetic factors associated with Type I diabetes…
Sep 3, 2024, 13:04 | Insight
Vivek Subbiah: Cancer remains the second leading cause of death after heart disease in the US, 2019-2023
Vivek Subbiah shared a post on LinkedIn: "Leading Causes of Death in the US, 2019-2023.…
Sep 2, 2024, 14:51 | Insight
Vivek Subbiah and Michelle Rengarajan - "Identification of ICI – Induced Diabetes"
Vivek Subbiah shared on LinkedIn: "Such a delight to host a podcast interview with Dr.…
Sep 1, 2024, 16:01 | Blog
Eric K. Singhi: Caring for the heart during cancer treatment
Eric K. Singhi shared on X: "Our care for patients with cancer is improved with a…
Sep 1, 2024, 15:26 | Insight
Guillermo Villacampa: Meta-analysis evaluating immunotherapy in early breast cancer
Recently, an article by Guillermo Villacampa et al. was published in JAMA Oncology. "Neoadjuvant Immune…
Aug 29, 2024, 16:48 | Insight
Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe
JAMA Oncology shared a post on X about a recent paper by Kamran Ahmed et…
Aug 22, 2024, 14:00 | Insight
Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…
Aug 19, 2024, 09:44 | Insight
Narjust Florez: Interesting and hypothesis provoking research letter in JAMA Oncology
Narjust Florez shared a post on X by JAMA Oncology about a recent paper by…
Aug 17, 2024, 08:07 | Insight
Liang Cheng: An exciting time to study bladder cancer
Liang Cheng shared on LinkedIn: "I am very happy to know that our collaborative research…
Aug 11, 2024, 13:12 | Insight
Bilateral Mastectomy and Breast Cancer Mortality
Elisa Agostinetto shared on X about a recent paper titled "Bilateral Mastectomy and Breast Cancer Mortality"…
Aug 10, 2024, 01:18 | Blog
JAMA Oncology Review: The Latest Treatment Options for Acute Myeloid Leukemia by Sylvester Comprehensive Cancer Center
Recently approved drugs are rapidly changing the treatment of patients with acute myeloid leukemia (AML),…
Aug 7, 2024, 12:06 | Blog
Miranda Ashitey: People are still shocked when I tell them men are susceptible to the BRCA1 and 2 mutation
Miranda Ashitey, Breast Cancer Blogger, shared a post by JAMA Oncology on X, adding: “People are…
Aug 5, 2024, 03:14 | Blog
Nina Niu Sanford: A balanced editorial of MR-guided RT
JAMA Oncology shared a post on X, about recent paper published in JAMA Oncology: MRI-Linac–Based…
Aug 3, 2024, 13:04 | Insight
Piotr Wysocki: Aspirin reduces the risk of colorectal cancer in individuals with unhealthy lifestyle
Piotr Wysocki shared on LinkedIn: "A study published in JAMA Oncology investigated the association between…
Jul 29, 2024, 13:42 | Blog
National screening guidelines for identifying the cancer risk of BRCA mutations in men - Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center shared a post on X: "Newly developed national screening guidelines offer…
Jul 28, 2024, 13:39 | Insight
Miguel Bronchud: Interesting apparent paradox pointed out on bilateral mastectomies
Miguel Bronchud, Co-Founder and Advisory Board at Regenerative Medicine Solutions, shared a post on LinkedIn:…
Jul 28, 2024, 09:27 | Insight
BRCA1, BRCA2, and Associated Cancer Risks for Male Patients
Yüksel Ürün shared on X about a recent paper by Heather Cheng et al. titled…
Jul 26, 2024, 15:32 | Insight
Piotr Wysocki: Physical exercise - a new, promising neoadjuvant treatment modality in prostate cancer?
Piotr Wysocki recently posted on LinkedIn: “A study published in JAMA Oncology analyzed the impact and…
Jul 22, 2024, 23:08 | Blog
Vivek Subbiah: A delight to host podcast on Neoadjuvant Exercise Therapy in Prostate Cancer
Vivek Subbiah shared a post on X by JAMA Oncology adding: "Such a delight to…
Jul 22, 2024, 15:02 | Insight
Immunotherapy use and effectiveness in Child-Pugh class B
JAMA Oncology shared a post on X about a paper titled "Immunotherapy vs Best Supportive…
Jul 19, 2024, 12:31 | Insight
Genetic Testing in Men With mCRPC
William Oh shared a post on LinkedIn about a recent paper by Pedro Barata et…
Jul 16, 2024, 13:55 | Blog
5 papers to read suggested by Vivek Subbiah
We are presenting articles suggested by Vivek Subbiah: 1.'Pancreatic Cancer Surveillance and Survival of High-Risk…
Jul 15, 2024, 08:33 | Insight
Vivek Subbiah: ASCO24 Highlights from the JAMA Network
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31st…
Jul 13, 2024, 12:13 | Insight
Vivek Subbiah: Great JAMA weekend read on highlights from ASCO24
Vivek Subbiah shared on LinkedIn: "Happy Friday, World! Hot off the press - published in…
Jul 10, 2024, 12:12 | Insight
Piotr Wysocki: Active surveillance in patients at high risk of pancreatic cancer may significantly improve their outcomes
Piotr Wysocki recently posted on LinkedIn: "Blackford AL et al. published results of a cohort study…
Jul 7, 2024, 07:19 | Insight
Adjuvant GemCis vs CRT with capecitabine in gallbladder cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X: "Adjuvant GemCis (gemcitabine and cisplatin)…
Jul 5, 2024, 05:08 | Blog
Pediatric patients are genetically prone to cancer benefit from early surveillance
St. Jude Children's Research Hospital shared on LinkedIn: "Research shows that pediatric patients genetically prone…
Jul 1, 2024, 10:01 | Blog
Stephen Chun: Long-term outcomes of IMRT for locally-advanced lung cancer
Stephen Chun made the following post on X: “Happy to report long-term outcomes of intensity modulated…
Jun 30, 2024, 16:30 | Insight
Veerle Geurts: Excellent outcome without chemotherapy for TNBC and high TILs
Veerle Geurts, PhD Candidate at The Netherlands Cancer Institute, shared on LinkedIn: “Patients with stage…
Jun 30, 2024, 12:56 | Blog
Vivek Subbiah: A delight to interview Dr. Kemi Doll
Vivek Subbiah shared on LinkedIn: "It was a delight to interview Dr. Kemi Doll a gynecologic…
Jun 29, 2024, 06:05 | Blog
Rachna Shroff: Our invited commentary on this important paper on pancreatic cancer
Rachna Shroff shared a post on X: “Congrats to Drs. Priyadarshini Pathak and Colin Weekes…
Jun 26, 2024, 09:54 | Insight
Miguel Bronchud: How often is post-recurrence treatment reported in adjuvant and neoadjuvant oncology randomized clinical trials?
Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared on LinkedIn: "Clinical trials- not “real life”? They…
Jun 26, 2024, 08:00 | Insight
New Paper Alert! Perioperative Modified FOLFIRINOX Improves Survival in Resectable Pancreatic Cancer: Results from a Phase 2 Trial
Perioperative Modified FOLFIRINOX Improves Survival in Resectable Pancreatic Cancer: Results from a Phase 2 Trial…
Jun 26, 2024, 03:57 | Insight
George Laliotis: Peri-operative FOLFIRINOX improved outcomes in patients with pancreatic cancer
George Laliotis, Translational Medicine Lead of GU Oncologist at Natera, shared a post by JAMA…
Jun 24, 2024, 01:26 | Blog
Timothée Olivier: Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X:…
Jun 23, 2024, 11:08 | Drugs
Vinay Prasad: We look at all Adjuvant and Neoadjuvant drugs approved by FDA in last 5 years
Vinay Prasad, Professor of Epidemiology and Biostatistics at the University of California, San Francisco, shared a…
Jun 22, 2024, 15:08 | Insight
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Anirban Maitra shared on X: "New in JAMA Oncology: Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer…
Jun 16, 2024, 04:13 | Insight
Most viewed in the last 7 days from JAMA Oncology
Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post by JAMA Oncology…
Jun 14, 2024, 14:42 | Insight
USPSTF recommends all women undergo routine breast cancer screening every other year beginning at age 40 - JAMA Oncology
JAMA Oncology shared on X/Twitter: "From JAMA: USPSTF recommends all women undergo routine breast cancer…
Jun 13, 2024, 05:48 | Blog
Rabab Hunaid Abbas: An exclusive keynote event with Dr. Thomas Marron
Rabab Hunaid Abbas, Member at Georgian International Medical Student Society, shared a post on LinkedIn: "Upcoming…
Jun 8, 2024, 10:07 | Insight
Ari Rosenberg: Our OPTIMA II trial is out in JAMA Oncology
Ari Rosenberg, Medical Oncologist and Assistant Professor at the University of Chicago, shared a post…
May 29, 2024, 09:25 | Insight
Biagio Ricciuti: The association of automatically extracted body composition metrics with IO efficacy in mNSCLC
Biagio Ricciuti, recently posted on X: "Out in JAMA Oncology! Our effort to determine the…
May 29, 2024, 09:17 | Societies
Cary Gross: Treating cancer in last 14 days of life can be harmful and wasteful
Cary Gross, Professor of Medicine at Yale University School of Medicine, recently shared on X:…
May 22, 2024, 04:25 | Blog
Timothée Olivier: One of the most important and practice-changing piece this year
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X…
May 12, 2024, 13:06 | Societies
Most viewed in the last 7 days from JAMA Oncology
JAMA Oncology shared on X: “Most viewed in the last 7 days from JAMA Oncology:  When…
May 11, 2024, 12:05 | Blog
Nina Niu Sanford: Nice editorial urging caution in patients with near CR after total neoadjuvant therapy in rectal cancer
Nina Niu Sanford, Assistant Professor of Radiation Oncology at UT Southwestern Medical Center, shared a…
May 8, 2024, 14:55 | Insight
Piotr Wysocki: 15-year colonoscopy interval is safe for individuals with no CRC history
Piotr Wysocki recently posted on LinkedIn: "A routine approach for individuals who had no negative…
May 7, 2024, 07:06 | Insight
Rashid Lui: Our thoughts on colonoscopy screening intervals with Professor Andrew Chan!
Rashid Lui, Head (Clinical Service) in Division of Gastroenterology and Hepatology at Hospital Authority, shared…
May 1, 2024, 09:30 | Blog
Giacomo Montagna: Thrilled to share our paper on the safety of axillary dissection omission
Giacomo Montagna, Breast surgeon at Memorial Sloan Kettering Cancer Center shared on X: “First post…
Apr 29, 2024, 11:56 | Blog
Nirmala Bhoo Pathy: A labor of love
Nirmala Bhoo Pathy shared a post on LinkedIn: "As peer reviewers, we often spend our weekends…
Apr 26, 2024, 20:41 | Insight
Piotr Wysocki: CAR-T therapy seems to be associated with second primary malignant neoplasms
Piotr Wysocki recently shared on LinkedIn: "In a research letter published online in JAMA Oncology,…
Apr 22, 2024, 19:17 | Blog
Ramy Sedhom on the Poetry by Antonio Yaghy
Ramy Sedhom, Clinical Director of Palliative Care at Penn Medicine Princeton Health, shared a post…
Apr 21, 2024, 18:22 | Blog
Vivek Subbiah: Pleased to host a podcast interview with Roni Shouval on Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Vivek Subbiah shared a post on X: “Secondary T-Cell Malignancies Following Chimeric antigen receptor (CAR) T-Cell…
Apr 16, 2024, 10:46 | Blog
Enes Erul: Excellent study at JAMA Oncology about symptom management for life extension
Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X: "Patients (%34) prioritized symptom management…
Apr 15, 2024, 12:30 | Blog
Vivek Subbiah: Using ePROs to prompt direct patient trial invitations
Vivek Subbiah shared a post on X: "Published in JAMA Oncology. Using ePROs to prompt direct…
Apr 11, 2024, 12:58 | Blog,Drugs
Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival - JAMA Oncology
JAMA Oncology shared on X/Twitter: "Most cancer drugs granted accelerated approval did not demonstrate benefit in…
Apr 6, 2024, 16:25 | Insight
New Article Alert! FOLFIRI plus durvalumab with or without tremelimumab in advanced gastric or GEJ adenocarcinoma
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal…
Apr 6, 2024, 07:42 | Blog
Early-stage triple-negative breast cancer treated with locoregional therapy only - JAMA Oncology
JAMA Oncology shared on X/Twitter: "In patients with early-stage triple-negative breast cancer treated with locoregional therapy…
Apr 3, 2024, 16:25 | Opinion
Matthew Kurian: Integrating AI into our everyday practice and decision-making
Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared…
Apr 3, 2024, 15:19 | Insight
Elisa Agostinetto: A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter: "Out…
Apr 3, 2024, 06:05 | Blog
Most viewed in the last 7 days from JAMA Oncology
JAMA Oncology shared a post on LinkedIn: “Most viewed in the last 7 days from…
Apr 2, 2024, 12:20 | Insight
Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology
Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared a post…
Mar 25, 2024, 15:56 | Blog
Vivek Subbiah: Such a delight to host a JAMA Oncology podcast interview with Tobias Janowitz and Karen Winkfield
Vivek Subbiah recently posted on X: “Such a delight to host a JAMA Oncology podcast…
Mar 24, 2024, 00:09 | Blog
Vivek Subbiah: Tune in to the podcast for insights into equitable access to cancer clinical trials
Vivek Subbiah posted on LinkedIn “Excited to announce my latest venture! Hosting an interview with…
Mar 23, 2024, 23:31 | Blog
Antonio Marra: Our review on current use and future development of PARP inhibitors in breast cancer just out in JAMA Oncology
Antonio Marra, Medical Oncologist at the European Institute of Oncology, on LinkedIn: “Excited to see…
Mar 13, 2024, 00:08 | Blog
A new paper on equitable trial methodologies has been published in JAMA Oncology - VCCC Alliance
VCCC Alliance posted the following on LinkedIn: "A new paper on equitable trial methodologies has…
Mar 8, 2024, 19:56 | Insight
Vivek Subbiah: How can we Modernize Precision Oncology With Decentralized Trial Tools?
Vivek Subbiah recently shared on LinkedIn: "Precision oncology has seen exciting developments in recent years with…
Mar 4, 2024, 12:09 | Blog
Nirmala Bhoo Pathy: Creating a culture that values and supports peer reviewers ensures the continued integrity and progress of scientific research
Nirmala Bhoo Pathy shared a post on LinkedIn: "Creating a culture that values and supports…
Feb 17, 2024, 17:47 | Insight
Vivek Subbiah: Delighted to share Modernize Precision Oncology With Decentralized Trial Tools
Vivek Subbiah shared a post on X: "Hot off the press JAMA Oncology: Delighted to…
Jan 22, 2024, 13:58 | Insight
Percy Lee: HyCRT-SABR for unresectable locally advanced NSCLC
Percy Lee, Professor and Vice-Chair of Clinical Research at City of Hope, shared on X/Twitter:…
Jan 7, 2024, 00:47 | Blog
Erman Akkus: Immunotherapy at the end-of-life
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: “Immunotherapy at the end-of-life…
Jan 2, 2024, 18:10 | Insight
Aleix Prat: Excited to unveil our lab's TOP-11 2023 research articles in breast cancer
Aleix Prat, Director of Cancer Institute at Hospital Clinic of Barcelona, shared on LinkedIn: "Excited to…
Jan 2, 2024, 15:04 | Insight
Jeff Ryckman: The Netherlands has consistently produced excellent research on the 'Good, Bad, and Ugly' categories
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University, shared a post by…
Dec 20, 2023, 18:28 | Blog
Fumiko Chino: Proud of this JAMA Oncology viewpoint from Dr. Justin Barnes discussing the negative cancer implications of Medicaid Unwinding
Fumiko Chino recently shared on X/Twitter: "'Forcing the most vulnerable people in the US off health…
Dec 6, 2023, 13:59 | Insight
Sheena Bhalla: Check out our recent JAMA Oncology Research Letter
Sheena Bhalla, Assistant Professor at UT Southwestern Medical Center, shared a post by JAMA Oncology on…
Dec 2, 2023, 17:44 | Insight
Marco Donia: Patients undergoing immunotherapy can safely receive SBRT upon indication
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Adding Stereotactic Body…
Nov 27, 2023, 17:43 | Blog
Paolo Tarantino: Can we get rid of the anthracyclines from the KN522 regimen?
Paolo Tarantino, Researcher at the European Institute of Oncology and clinical research fellow at the…
Nov 24, 2023, 01:03 | Blog
Bishal Gyawali: We urge to exercise some caution before we start treating “pre-patients” for cancer risk factors!
Bishal Gyawali, Associate Professor at Queen's University, made the following post on LinkedIn: "In our…
Oct 31, 2023, 10:11 | Blog
Yao Yu: Happy to share our work on Stereotactic radiosurgery with concurrent Antibody Drug Conjugates
Yao Yu, Radiation Oncologist at Memorial Sloan Kettering Cancer Center, shared on X/Twitter: "Happy to…
Oct 20, 2023, 20:13 | Insight
Aman Chauhan: We will continue to work on NEC and SCLC and hopefully find a breakthrough
Aman Chauhan, Leader of Neuroendocrine Cancer Program at the Sylvester Comprehensive Cancer Center, shared on his…
Oct 9, 2023, 00:35 | Drugs
Arndt Vogel: Off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC JAMA Oncology.
Arndt Vogel, made the following post on Twitter: "Off the press: Tislelizumab vs Sorafenib as 1st…
Oct 3, 2023, 18:09 | Blog
Mohamed Derbala: Excited to share our latest editorial in JAMA Oncology.
Quoting Mohamed Derbala, Research Scientist at the MD Anderson Cancer Center, on X/Twitter: "Excited to…
Aug 25, 2023, 18:25 | Insight
Arndt Vogel: Immune Checkpoint Inhibitors for Child-Pugh B HCC: comprehensive summary of 22 studies with 699 patients.
Quoting Arndt Vogel on X/Twitter: "Hot off the press: Immune Checkpoint Inhibitors for CP B…
Aug 20, 2023, 17:45 | Insight
Todd Scarbrough: Today I saw a lot of radonc shouting at the NEJM clouds.
Quoting Todd Scarbrough, Radiation Oncologist at Northeast Alabama Regional Medical Center on Twitter: "Today I…
Aug 1, 2023, 20:08 | Positive
Great group! Great vision! - H. Jack West
In Chicago for a high energy annual JAMA Oncology Editorial Board meeting where we review…
Jul 24, 2023, 18:23 | Drugs
These drugs are $$$! i.e. avapritinib = $44,000/bottle - Michael Lam
Patients on oral chemo after dose reduction: "I still have these pills at home, but…
All: 87 Posts: 1 - 100
Special Coverage